Skip to main content
Premium Trial:

Request an Annual Quote

Phenomix Inks Deal with Genentech

NEW YORK, July 12 (GenomeWeb News) - Phenomix said today that it has signed a deal to help Genentech identify and prioritize drug targets for the treatment of immune disorders.


Under the terms of the multi-year deal, Phenomix will use its forward genetics technology to identify new disease targets in immunology. Genentech will have the exclusive global rights to develop therapeutics using the targets, while Phenomix retains the rights to develop undisclosed products based on certain targets.


Phenomix said it will receive an upfront fee and an equity investment from Genentech, as well as research funding and milestones. Additional terms were not disclosed.


The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.